SCHEMBL146329

SCHEMBL146329

Nc1ccccc1C(=O)C[C@H](NC=O)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.42
ALDH1A1 P00352 8/20 0.42
MAPT P10636 3/20 0.40
GAA P10253 1/20 0.40
HSD17B10 Q99714 5/20 0.39
CFTR P13569 1/20 0.39
HIF1A Q16665 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
HDAC1 Q13547 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 4/20 0.38
TSHR P16473 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
TP53 P04637 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
L-Kynurenine SCHEMBL9636977 0.93 KDM4E (0.49) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL3501286 0.85 ALDH1A1 (0.40) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL5388881 0.83 MAPT (0.43) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL288333 0.83 MAPT (0.43) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL19273911 0.82 GAA (0.46) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL4996617 0.82 MAPT (0.42) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL18796376 0.82 GAA (0.46) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL1331881 0.82 KMT2A (0.40) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL29922241 0.81 ALDH1A1 (0.38) KDM4EALDH1A1MAPTGAAHSD17B10
SCHEMBL9242281 0.79 MAPT (0.40) KDM4EALDH1A1MAPTGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2268 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4667453-A1 METHOD FOR PRODUCING TRYPTOPHAN DECOMPOSITION PRODUCT, METHOD FOR PRODUCING FORMYLKYNURENINE, METHOD FOR PRODUCING KYNURENINE, METHOD FOR PRODUCING TRYPTOPHANRADICALS-CONTAINING AQUEOUS SOLUTION, AND BACTERICIDAL AQUEOUS SOLUTION NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2025-12-24 EP claimed
EP-4648788-A1 LIPID BINDING PROTEIN MOLECULE THERAPY Abionyx Pharma SA (FR) 2025-11-19 EP claimed
EP-3831379-B1 A COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA CONARIS RES INSTITUTE AG (DE) 2025-09-10 EP claimed
US-20250213549-A1 COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES CONARIS RESEARCH INSTITUTE AG (DE) 2025-07-03 US claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
CN-114938659-B Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof 中国医学科学院阜外医院 2025-03-04 CN claimed
WO-2024150064-A9 LIPID BINDING PROTEIN MOLECULE THERAPY ABIONYX PHARMA SA (FR) 2025-02-20 WO claimed
CN-119391580-A Lactobacillus rhamnosus capable of preventing or treating inflammatory bowel disease and promoting digestion and application thereof 内蒙古科拓生物有限公司 2025-02-07 CN claimed
EP-4499059-A1 COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES CONARIS research institute AG (DE) 2025-02-05 EP claimed
US-12103960-B2 VEGF traps and mini-traps and methods for treating ocular disorders and cancer REGENERON PHARMACEUTICALS, INC. (US) 2024-10-01 US claimed
US-20110300142-A1 USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS IDOGEN AB (SE) 2011-12-08 US claimed
US-20100261774-A1 Methods for the modulation of Leishmania major infection in mammals CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2010-10-14 US claimed
EP-2164500-A1 THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS Idogen AB (SE) 2010-03-24 EP claimed
US-20090208565-A1 STABILIZED EXENDIN-4 COMPOUNDS ZEALAND PHARMA A/S (DK) 2009-08-20 US claimed
WO-2008147283-A1 THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS SALFORD LEIF (SE) 2008-12-04 WO claimed
US-20080090223-A1 Method for Diagnosing Hepatic Diseases PROYECTO DE BIOMEDICINA CIMA, S.L. (ES) 2008-04-17 US claimed
US-20060194719-A1 Stabilized exendin-4 compounds ZEALAND PHARMA A/S (DK) 2006-08-31 US claimed
EP-1546200-A2 STABILIZED EXENDIN-4 COMPOUNDS Zealand Pharma A/S (DK) 2005-06-29 EP claimed
WO-2004035623-A2 STABILIZED EXENDIN-4 COMPOUNDS ZEALAND PHARMA A/S (DK) 2004-04-29 WO claimed
EP-1369114-A1 Use of tryptophan metabolites as pharmaceutical agents Terness, Peter, Priv. Doz. Dr. (DE) 2003-12-10 EP claimed